Because of the difficulty associated with managing bleeding,<unk>  should be discontinued at least 24 hours before surgery, then restarted as soon as adequate hemostasis is established. Dosing recommendations do not recommended administering<unk>  with drugs known to be strong combined CYP3A4/P-glycoprotein inhibitors because this results in significantly higher plasma concentrations of<unk> .
Rivaroxaban
Apixaban
Dabigatran
Ticlopidine
Enoxaparin sodium
Ticagrelor
Eptifibatide
Palladin